Showing results (31-40 of 57) with videos related to
Sort By:
Pageof 6
Organic & Biomolecular Chemistry|November 12, 2013
Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocyclesHonorine Lebraud, Christopher R Coxon, Victoria S Archard, et al.Oncotarget|June 22, 2016
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiationCatherine J Drummond, Arman Esfandiari, Junfeng Liu, et al.Plos One|October 12, 2012
Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancerKelly Coffey, Timothy J Blackburn, Susan Cook, et al.Medchemcomm|October 1, 2013
Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluation. Further details for the modeling. Table of combustion analysis data. See DOI: 10.1039/c3md00161jClick here for additional data fileTim J Blackburn, Shafiq Ahmed, Christopher R Coxon, et al.Journal of Medicinal Chemistry|March 13, 2019
FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit GenerationDaniel J Wood, J Daniel Lopez-Fernandez, Leanne E Knight, et al.Organic & Biomolecular Chemistry|February 23, 2018
Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approachDuncan C Miller, Mathew P Martin, Santosh Adhikari, et al.RSC Medicinal Chemistry|January 22, 2021
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinaseChristopher J Matheson, Christopher R Coxon, Richard Bayliss, et al.Oncotarget|November 12, 2016
Structure-guided design of purine-based probes for selective Nek2 inhibitionChristopher R Coxon, Christopher Wong, Richard Bayliss, et al.Journal of Medicinal Chemistry|December 6, 2013
8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding modeBenoit Carbain, David J Paterson, Elizabeth Anscombe, et al.Journal of Medicinal Chemistry|July 17, 2013
1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activityCéline Cano, Kappusamy Saravanan, Chris Bailey, et al.Pageof 6